BLFS at a glance
BIOLIFE SOLUTIONS INC (BLFS, SEC CIK 834365) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $96.2 million (up 17.0% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.10.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding BIOLIFE SOLUTIONS INC (BLFS) shares worth $763.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $96.2M
- +17.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $763.4M · +3 vs prior quarter
- Latest 8-K
- Oct 6, 2026
- Item 3.03 · Item 5.02 · Item 2.01 · Item 3.01 · Item 5.03 · Item 5.01 · Item 5.07
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $28.5M, up $5.0M or 21% YoY, driven by biopreservation media demand
- Gross margin 64% vs 65% YoY, reflecting less favorable product mix and higher lower-margin sales
- Best-performing offering biopreservation media, with demand driving quarterly revenue growth
- Cash, equivalents and securities $113.1M vs $120.2M at December 31, 2025
- Six-month operating cash flow $5.9M vs $9.1M; $11.5M financing outflow included $6.7M tax-withholding payments
Risk Factors
- Risk factors section not provided; supplied text contains Items 2–6 and signatures only
- Merger agreement dated July 21, 2026, with Repligen Corporation and merger subsidiaries disclosed as an exhibit
AI summary of the BLFS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.03: Material Modification to Rights of Security Holders
- First merger completed, ending existing BioLife common stockholder rights
- Non-dissenting holders entitled only to merger consideration for their shares
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger-driven replacement of BioLife’s entire seven-member board, eliminating the pre-transaction governance team
- Merger Sub 1 directors and officers assumed BioLife leadership roles at the First Merger Effective Time
Item 2.01: Completion of Acquisition or Disposition of Assets
- Acquisition completed, with each BioLife share converted into 0.1442 Repligen shares plus $11.25 cash
- Transaction consideration combines equity participation with immediate cash value for BioLife shareholders
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- BioLife ceased as a separate legal entity following the Mergers, eliminating its Nasdaq listing eligibility
- Nasdaq trading halted after the October 5, 2026 after-market session
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Merger-triggered restatement of BioLife’s certificate of incorporation and bylaws effective at the First Merger Effective Time
- Governance documents replaced in full, signaling post-merger changes to corporate structure and shareholder rights
Item 5.01: Changes in Control of Registrant
- Completed mergers triggered a change in control of BioLife Solutions
- BioLife became a wholly owned subsidiary of Repligen
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger Agreement adopted, clearing the key shareholder approval needed for Repligen’s acquisition of BioLife
- Proposal 1 received 40,910,337 votes for versus 83,451 against, an overwhelming approval margin
Item 8.01: Other Events
- HSR antitrust waiting period expired September 3, clearing a key regulatory condition for Repligen’s acquisition of BioLife
- Consideration remains $11.25 cash plus 0.1442 Repligen shares per BioLife share
Item EX-99.1: Item EX-99.1
- Q2 revenue $28.5M, up 21% year over year, with adjusted EBITDA $7.4M and 26% margin
- GAAP gross margin 64%, down from 65%, while adjusted gross margin declined to 65% from 66%
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 unaudited results for quarter ended June 30, 2026
- Operational highlights announced August 6, 2026
AI summaries of BLFS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BLFS
Don't miss the next BLFS filing
- Alerts as it files. A push when BLFS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BLFS, by share count.
- Ask anything. An AI agent that reads every BLFS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DuRoss Amy | D | Oct 6, 2026 | 26,857 | - |
| DE GREEF RODERICK | A | Oct 6, 2026 | 225,670 | - |
| Ellingson Rachel | D | Oct 6, 2026 | 57,995 | - |
| Wichterman Troy | F | Oct 6, 2026 | 95,933 | $38.61 |
| Wichterman Troy | A | Oct 6, 2026 | 76,204 | - |
| Coste Catherine | D | Oct 6, 2026 | 13,871 | - |
| Wichterman Troy | D | Oct 6, 2026 | 256,000 | - |
| GOSWAMI JOYDEEP | D | Oct 6, 2026 | 53,156 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $82.3M | $96.2M |
| Gross Profit | $41.3M | $50.1M | $62.1M |
| Operating Income | - | -$7.1M | -$16.6M |
| Net Income | - | -$20.2M | -$4.6M |
| Gross Margin | - | 60.9% | 64.6% |
| Op. Margin | - | -8.7% | -17.3% |
| Net Margin | - | -24.5% | -4.8% |
| Balance Sheet | |||
| Total Assets | - | $399.5M | $405.9M |
| Equity | - | $348.9M | $371.9M |
| ROE | - | -5.8% | -1.2% |
| Per Share | |||
| EPS | $-1.52 | $-0.44 | $-0.10 |
| Cash Flow | |||
| Operating CF | - | $8.4M | $20.1M |
| CapEx | - | $3.2M | $9.5M |
Source: XBRL data in BIOLIFE SOLUTIONS INC (BLFS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BLFS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $763.4M |
| Q2 2026 | 28 | $561.4M |
| Q1 2026 | 26 | $383.8M |
| Q4 2025 | 25 | $518.5M |
| Q3 2025 | 27 | $522.3M |
| Q2 2025 | 27 | $424.2M |
| Q1 2025 | 24 | $318.9M |
| Q4 2024 | 20 | $327.4M |
- Goldman Sachs Group+1.29M (+243%)
- BlackRock+298.2K (+5%)
- Millennium Management+147.0K (+23%)
- D.E. Shaw & Co+82.6K (+669%)
- Vanguard Capital Management LLC+31.4K (+2%)
- Invesco Ltd−994.8K (-44%)
- Raymond James Financial−427.5K (-98%)
- Bank of America Corp−321.2K (-34%)
- Citadel Advisors LLC−123.2K (-78%)
- Wells Fargo & Co−104.9K (-91%)
- Soros Fund Management+671.0K
- Renaissance Technologies LLC+125.0K
- Bridgewater Associates LP+97.0K
- Two Sigma Investments+38.0K
- FMR LLC (Fidelity)−993.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BLFS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 8, 2026 | - | - | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| SC 13G | Sep 24, 2026 | - | - | |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
BLFS SEC filings: frequently asked questions
Which institutions hold BLFS stock?
As of September 30, 2026, the largest BIOLIFE SOLUTIONS INC (BLFS) holders among the 13F filers tracked by SignalX were BlackRock ($259.3 million), Vanguard Capital Management LLC ($77.5 million), Goldman Sachs Group ($70.7 million), State Street Corp ($64.2 million), Invesco Ltd ($48.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BLFS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BIOLIFE SOLUTIONS INC (BLFS) reported revenue of $96.2 million (up 17.0% from FY2024) and a net loss of $4.6 million. Diluted EPS was -$0.10. The figures come from the XBRL data in the 10-K.
What did BLFS report in its latest 8-K?
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K on October 6, 2026 reporting Item 3.03 (Material Modification to Rights of Security Holders), Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.01 (Changes in Control of Registrant) and Item 5.07 (Submission of Matters to a Vote of Security Holders). First merger completed, ending existing BioLife common stockholder rights.
What are the latest BLFS SEC filings?
BIOLIFE SOLUTIONS INC (BLFS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 6, 2026 and a Form 4 insider filing on October 8, 2026.
What is BLFS's SEC CIK number?
BIOLIFE SOLUTIONS INC (BLFS)'s SEC Central Index Key (CIK) is 834365. EDGAR lists every BLFS filing under that number.
Ask anything about BLFS
The research agent reads BLFS's filings, financials, insider trades and 13F holders, then answers with sources.